NeuroStar Advanced Therapy
Major Depressive Disorder (MDD)
Key Facts
About Neuronetics
Neuronetics' mission is to provide safe, effective neuromodulation therapies for patients with psychiatric disorders who have not benefited from first-line treatments. The company has achieved commercial success with its NeuroStar TMS system, establishing it as a leading brand with over 8.2 million treatments delivered and securing broad insurance coverage. Its strategy focuses on expanding clinical indications, driving provider adoption, and leveraging a razor-and-blades business model anchored in capital equipment sales and recurring revenue from treatment sessions.
View full company profileAbout Neuronetics
Neuronetics' mission is to provide safe, effective neuromodulation therapies for patients with psychiatric disorders who have not benefited from first-line treatments. The company has achieved commercial success with its NeuroStar TMS system, establishing it as a leading brand with over 8.2 million treatments delivered and securing broad insurance coverage. Its strategy focuses on expanding clinical indications, driving provider adoption, and leveraging a razor-and-blades business model anchored in capital equipment sales and recurring revenue from treatment sessions.
View full company profileAbout Neuronetics
Neuronetics' mission is to provide safe, effective neuromodulation therapies for patients with psychiatric disorders who have not benefited from first-line treatments. The company has achieved commercial success with its NeuroStar TMS system, establishing it as a leading brand with over 8.2 million treatments delivered and securing broad insurance coverage. Its strategy focuses on expanding clinical indications, driving provider adoption, and leveraging a razor-and-blades business model anchored in capital equipment sales and recurring revenue from treatment sessions.
View full company profileAbout Neuronetics
Neuronetics' mission is to provide safe, effective neuromodulation therapies for patients with psychiatric disorders who have not benefited from first-line treatments. The company has achieved commercial success with its NeuroStar TMS system, establishing it as a leading brand with over 8.2 million treatments delivered and securing broad insurance coverage. Its strategy focuses on expanding clinical indications, driving provider adoption, and leveraging a razor-and-blades business model anchored in capital equipment sales and recurring revenue from treatment sessions.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |
| Flow tDCS Headset & App | Flow Neuroscience | Approved |